In late 2011, Whitney Tilson shared a presentation on his website in which he conducts an analysis of Berkshire Hathaway (BRK.A)(BRK.B) and arrives at an estimate of Berkshire Hathaway�� Intrinsic Value. Basically, Tilson went through several Berkshire Hathaway annual reports and highlighted several of Warren Buffett's comments where Buffett talks about the discrepancy in Berkshire's stock price and its intrinsic value. Tilson then focuses on a quote and chart that could be found by reading the1997 Berkshire Hathaway Chairman's Letter:
In our last two annual reports, we furnished you a table that Charlie and I believe is central to estimating Berkshire's intrinsic value. In the updated version of that table, which follows, we trace our two key components of value. The first column lists our per-share ownership of investments (including cash and equivalents) and the second column shows our per-share earnings from Berkshire's operating businesses before taxes and purchase-accounting adjustments (discussed on pages 69 and 70), but after all interest and corporate expenses. The second column excludes all dividends, interest and capital gains that we realized from the investments presented in the first column. In effect, the columns show what Berkshire would look like were it split into two parts, with one entity holding our investments and the other operating all of our businesses and bearing all corporate costs.
Pre-tax Earnings Per Share
Investments/Share Excluding All Income from investments
1967 $ 41 $ 1.09
1977 372 12.44
1987 3,910 108.14
1997 38,043 717.82What Tilson then does is take Berkshire's Investment's Per Share at book value and applies a multiple to Berkshire's pre-tax earnings per share that excludes all income from investments. Pretty straightforward right? It's definitely an alternative to some of the "sum of the parts" analysis I have seen from other individuals such as Tom Gayner's in the June 30, 2011 ed! ition of Value Investor Insight.While the approach is straightforward and makes sense, Berkshire's new share repurchase plan may have changed things a bit.
Top 5 Warren Buffett Stocks To Own Right Now: Enersis S A(ENI)
Enersis S.A., an electric utility company, engages in the generation, transmission, and distribution of electricity in Chile, Argentina, Brazil, Colombia, and Peru. It owns and operates hydroelectric, thermal, and wind power plants. As of December 31, 2010, it had 14,833 megawatts of installed capacity with 195 power plants; and 13.3 million distribution customers covering approximately 50 million inhabitants. The company was formerly known as Compania Chilena Metropolitana de Distribucion Electrica S.A and changed its name to Enersis S.A. in August 1988. Enersis S.A. was founded in 1889 and is headquartered in Santiago, Chile. Enersis S.A. is a subsidiary of Endesa Latinoamerica S.A.
Advisors' Opinion:- [By Sofia Horta e Costa]
European stocks were little changed at a one-week high as companies from Eni SpA (ENI) to Volkswagen AG posted profit that exceeded estimates, while a gauge of telecommunications companies retreated.
Top 5 Warren Buffett Stocks To Own Right Now: Motricity Inc.(MOTR)
Motricity, Inc. enables mobile operators, brands, and advertising agencies to maximize the reach and economic potential of the mobile ecosystem through the delivery of relevance-driven merchandising, marketing, and advertising solutions. It leverages predictive analytics capabilities to deliver the right content, to the right person at the right time. Motricity, Inc. provides their entire suite of mobile data service solutions through a managed service platform. The company was formerly known as Power By Hand, Inc. and changed its name to Motricity, Inc. in October 2004. Motricity, Inc. was incorporated in 2004 and is headquartered in Bellevue, Washington.
Hot Oil Stocks To Own Right Now: Amgen Inc.(AMGN)
Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. The company markets recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body to fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body?s response to inflammatory diseases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides Denosumab, a human monoclonal antibody that targets RANKL, an essential regulator of osteoclasts. Further, the company offers product candidates in mid-to-late stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone, nephrology, cardiovascular, and general medicine consisting of neurology. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. The company has various collaborative arrangements with Pfizer Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company, Limited; Array BioPharma Inc.; Kyowa Hakko Kirin Co. Ltd.; and Cytokinetics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Advisors' Opinion:- [By Monica Gerson]
Amgen (NASDAQ: AMGN) is expected to post its Q3 earnings at $1.77 per share on revenue of $4.60 billion.
Broadcom (NASDAQ: BRCM) is estimated to post its Q3 earnings at $0.69 per share on revenue of $2.13 billion.
- [By Ben Levisohn]
After weeks of speculation, Amgen’s (AMGN) purchase of Onyx Pharmaceuticals (ONXX) looks like a done deal. The Wall Street Journal has the details:
Associated PressAmgen�Inc. reached a deal Sunday to buy fellow biotech�Onyx Pharmaceuticals�Inc. for roughly $10.4 billion, the latest proposed takeover aimed at tapping into growth expected from the cancer-drug industry.
The all-cash takeover values Onyx at $125 a share. The price Amgen is paying is below what investors expected in the days after the possible deal surfaced in late June. Amgen had approached Onyx with an offer of $120 a share for the company, whose primary attraction is a blood-cancer drug called Kyprolis…
The deal is expected to close at the beginning of the fourth quarter.
RBC’s Michael Yee and team list three reasons for Amgen stockholders to like the deal:
We reiterate our view AMGN will likely go higher after acquiring ONXX because: 1) adds growth ��changes the growth profile of AMGN and modestly accelerates top/bottom line (we see 5-15% accretion…), 2) diversification: it diversifies AMGN away from current portfolio of supportive care drugs where over 40% is exposed to biosimilars over next few years so it reduces biosimilar risk, 3) adds leverage through OUS infrastructure, reimbursement expertise, and existing cancer salesforce (tougher for small co’s).
Amgen has gained 8.5% to $114.54 and Onyx has risen 5.7% to $123.64.
Cantor Fitzgerald’s Mara Goldstein and Adeyemi Ogunkoya consider what the deal says about the current state of the biotech market–and the recent biotech rally (the SPDR S&P Biotech ETF (XBI) has gained 38% this year):
Because of the ebb and flow of pipelines in the drug development industry, valuations for biotech companies may also rise and fall depending on a given cycle. The last few years has been one of large cap industry pipeline ebb, and that suggests to us t
Top 5 Warren Buffett Stocks To Own Right Now: Blonder Tongue Laboratories Inc. (BDR)
Blonder Tongue Laboratories, Inc. operates as a technology-development and manufacturing company primarily in the United States. It delivers television (TV) signal encoding, transcoding, digital transport, and broadband product solutions for a range of applications. The company offers analog video headend products, including integrated receiver/decoders, modulators, demodulators, channel combiners, and processors for use by system operators for signal acquisition, processing, and manipulation to create an analog channel lineup for further transmission. It also provides digital video headend products comprising high definition (HD) and standard definition MPEG-2 encoders and multiplexers, as well as quadrature phase shift key to quadrature amplitude modulation (QAM) transcoders, digital QAM up-converters, and multiplexers; and digital 8VSB/QAM HDTV processors for the delivery of HDTV programming; and agile QAM Modulators. The company offers its digital video headend product s for use by system operators for the acquisition, processing, and manipulation of digital video signals. In addition, it provides hybrid fiber-coax (HFC) distribution products comprising broadband amplifiers, directional taps, splitters, and wall outlets for coax distribution and fiber optic transmitters, receivers, and couplers. The company offers its HFC distribution products to transport signals from the headend to homes, apartment units, hotel rooms, offices, or other terminal location along a fiber optic, coax, or HFC distribution network. It serves TV broadcasters, cable system operators, and lodging/hospitality video and high-speed Internet system operators, as well as institutional system operators or contractors that serve schools, universities, hospitals, prisons, corporations, sports stadiums, and airports. The company sells its products through sales force and stocking distributors. Blonder Tongue Laboratories, Inc. was founded in 1950 and is headquartered in Ol d Bridge, New Jersey.
Advisors' Opinion:- [By Geoff Gannon]
Bells should be ringing when you read that. Look at AEY�� business versus that of a competitor like Blonder Tongue (BDR). I�� just going to use GuruFocus data here. You can find the 10-year financial data for BDR here and the 10-year financial data for AEY here.
Top 5 Warren Buffett Stocks To Own Right Now: First Niagara Financial Group Inc.(FNFG)
First Niagara Financial Group, Inc. operates as the holding company for First Niagara Bank, N.A. that provides retail and commercial banking, and other financial services to individuals, families, and businesses. It offers retail deposit accounts, which include savings, negotiable order of withdrawal, checking, money market, and certificate of deposit accounts, as well as provides business savings and checking, money market, cash management accounts, and municipal deposit accounts. The company?s loan portfolio comprises commercial real estate and multi-family loans; commercial business loans; residential real estate loans; home equity loans; and consumer loans consisting of indirect mobile home loans, and personal secured and unsecured loans. It also sells insurance products, including commercial and personal insurance, surety bond, life, disability, and long-term care coverage products. In addition, the company offers risk management consulting services comprising altern ative risk and self-insurance services, claims investigation and adjusting services, and third party administration services for self insured workers? compensation plans. Further, it provides employee benefits plan and compensation consulting services. Additionally, First Niagara Financial Group offers wealth management services that manage client funds utilizing various third party investment vehicles consisting of stocks, bonds, mutual funds, and annuities, as well as other investment products, such as individual retirement accounts, education savings plans, and retirement plans. As of December 31, 2010 it operated 257 bank branches, including 115 in Upstate New York and 142 branches in Pennsylvania. The company was founded in 1870 and is based in Buffalo, New York.
Advisors' Opinion:- [By Rick Munarriz]
Friday
Things are usually quiet on Fridays, but that won't stop First Niagara Financial Group (NASDAQ: FNFG ) from reporting. The parent company of First Niagra Bank -- a community banker with 430 branches and $37 billion in assets -- is expect to post marginal improvement on the top and bottom lines. - [By John Maxfield]
Given that you clicked on this article, it seems safe to assume you either own stock in First Niagara Financial (NASDAQ: FNFG ) or are considering buying shares in the near future. If so, then you've come to the right place. The table below reveals the nine most critical numbers investors need to know about First Niagara Financial stock before deciding whether to buy, sell, or hold it.
- [By Monica Gerson]
First Niagara Financial Group (NASDAQ: FNFG) is projected to report its Q3 earnings at $0.19 per share on revenue of $365.77 million.
Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets
- [By John Maxfield]
While it's not obvious from the chart, you can separate these institutions into three different buckets. The first bucket concerns the most widely discussed too-big-to-fail banks: JPMorgan Chase, Bank of America, Citigroup, and Wells Fargo. Then comes the unofficial too-big-to-fail lenders (those with assets in excess of $50 billion and thus subject to the Federal Reserve's more stringent stress test process). This group contains U.S. Bank (NYSE: USB ) , PNC Financial (NYSE: PNC ) , and BB&T Bank (NYSE: BBT ) , among others. And the final group encompasses lesser-known banks like First Niagara Financial (NASDAQ: FNFG ) and People's United Financial (NASDAQ: PBCT ) with between $20 billion and $50 billion in assets.
No comments:
Post a Comment